Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COMPASS Pathways plcCMPS · Entity 4567 | Director | May 27, 2026 | May 29, 2026 |
| Kailera Therapeutics, Inc.KLRA · Entity 4435 | See Remarks | July 06, 2026 | July 08, 2026 |
| Spero Therapeutics, Inc.SPRO · Entity 7014 | Director | June 23, 2026 | June 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COMPASS Pathways plc
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2036-05-26 | Direct | 41,119 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 41,119 · Balance 41,119 F1: This option shall vest in 36 equal monthly installments over three years, with the first tranche vesting and becoming exercisable on June 27, 2026. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in 36 equal monthly installments over three years, with the first tranche vesting and becoming exercisable on June 27, 2026.
F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Kailera Therapeutics, Inc.
Report date July 06, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.30 · Expires 2036-07-06 | Direct | 175,000 |
Reported balance
After 2026-07-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-06 · Grant · Acquired 175,000 · Balance 175,000 F1: The options vest and become exercisable as to 25% of the underlying shares on June 29, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable as to 25% of the underlying shares on June 29, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
Spero Therapeutics, Inc.
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,000 |
Reported balance
After 2026-06-23 transaction · row 1
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 10,000 · Balance 85,000 F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.15 · Expires 2036-06-23 | Direct | 20,000 |
Reported balance
After 2026-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-23 · Grant · Acquired 20,000 · Balance 20,000 F2: The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date.
F2: The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cerevel Therapeutics Holdings, Inc.
Report date August 01, 2024 · Filed August 05, 2024
Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 1
1 source rowRow 1 · 2024-08-01 · Disposition to issuer · Disposed 10,666 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-08-01 · Disposition to issuer · Disposed 614,428 · Balance 0 F2: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-01 · Disposition to issuer · Disposed 59,171 · Balance 0 F3: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.
F2: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
F3: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2026 Filed Jul 8, 2026 20:20 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $23.30 | $0.00 |
DisclosureSEC source: 0001193125-26-298558 · ownership.xml · derivative · entry 1 Tregoning Kathleen · CIK 0001830764 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2036-07-06 F1 · derivative.exercise_date: The options vest and become exercisable as to 25% of the underlying shares on June 29, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 23:17 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001193125-26-283238 · ownership.xml · derivative · entry 2 Tregoning Kathleen · CIK 0001830764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-06-23 F2 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 23:17 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-283238 · ownership.xml · nonDerivative · entry 1 Tregoning Kathleen · CIK 0001830764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 27, 2026 Filed May 29, 2026 21:10 UTC | COMPASS Pathways plc CMPS · Entity 4567 | GrantShare Option (Right to Buy) · Derivative | 41,119 | $0.00 Strike: $11.85 | $0.00 |
DisclosureSEC source: 0001830764-26-000004 · wk-form4_1780089046.xml · derivative · entry 1 Tregoning Kathleen · CIK 0001830764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,119 Underlying: Ordinary Shares · 41,119 shares Expires 2036-05-26 F1 · derivative.exercise_date: This option shall vest in 36 equal monthly installments over three years, with the first tranche vesting and becoming exercisable on June 27, 2026. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:24 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-087008 · ownership.xml · nonDerivative · entry 1 Tregoning Kathleen · CIK 0001830764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 12, 2026, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:29 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerRestricted Stock Units · Derivative | 59,171 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-090822 · ownership.xml · derivative · entry 3 Tregoning Kathleen · CIK 0001830764 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,171 shares Expires not disclosed F3 · derivative.exercise_price: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. F3 · derivative.expiration_date: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:29 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerStock Option (Right to Buy) · Derivative | 614,428 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090822 · ownership.xml · derivative · entry 2 Tregoning Kathleen · CIK 0001830764 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 614,428 shares Expires not disclosed F2 · derivative.exercise_price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F2 · price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F2 · derivative.exercise_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F2 · derivative.expiration_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:29 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerCommon Stock | 10,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090822 · ownership.xml · nonDerivative · entry 1 Tregoning Kathleen · CIK 0001830764 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:25 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-066624 · ownership.xml · nonDerivative · entry 1 Tregoning Kathleen · CIK 0001830764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on May 29, 2025, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 17:46 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantRestricted Stock Units · Derivative | 59,171 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-006696 · ownership.xml · derivative · entry 1 Tregoning Kathleen · CIK 0001830764 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,171 Underlying: Common Stock · 59,171 shares Expires not disclosed F1 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date. F1 · derivative.exercise_date: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date. F1 · derivative.expiration_date: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:40 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 35,604 | $1.12 Strike: $1.52 | $39,876.48 |
DisclosureSEC source: 0000950170-24-001971 · ownership.xml · derivative · entry 1 Tregoning Kathleen · CIK 0001830764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,604 Underlying: Common Stock · 35,604 shares Expires 2034-01-02 F2 · price: This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $40,000 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy. F1 · derivative.exercise_date: This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,150 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000950170-23-073592 · ownership.xml · derivative · entry 2 Tregoning Kathleen · CIK 0001830764 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,082 Underlying: Common Stock · 3,150 shares Expires 2030-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on July 28, 2021, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 3,150 | $10.05 | $31,657.50 |
DisclosureSEC source: 0000950170-23-073592 · ownership.xml · nonDerivative · entry 1 Tregoning Kathleen · CIK 0001830764 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 20:10 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 6,288 | $41.42 | $260,469.08 |
DisclosureSEC source: 0000950170-23-072363 · ownership.xml · nonDerivative · entry 2 Tregoning Kathleen · CIK 0001830764 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,516 F3 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.36 to $41.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 20:10 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionRestricted Stock Units · Derivative | 13,804 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-072363 · ownership.xml · derivative · entry 3 Tregoning Kathleen · CIK 0001830764 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,804 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represented the contingent right to receive one share of the Issuer's common stock. F1 · kind: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. F1 · derivative.exercise_date: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. F1 · derivative.expiration_date: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 20:10 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 13,804 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-072363 · ownership.xml · nonDerivative · entry 1 Tregoning Kathleen · CIK 0001830764 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. F2 · price: Each RSU represented the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| October 05, 2023 Filed Oct 10, 2023 21:29 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-052703 · ownership.xml · nonDerivative · entry 1 Tregoning Kathleen · CIK 0001830764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on October 5, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 20:30 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantRestricted Stock Units · Derivative | 13,804 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-004364 · doc4.xml · derivative · entry 2 Tregoning Kathleen · CIK 0001830764 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,804 Underlying: Common Stock · 13,804 shares Expires not disclosed F2 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date. F3 · derivative.expiration_date: The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 20:30 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 54,320 | $0.00 Strike: $34.41 | $0.00 |
DisclosureSEC source: 0000899243-23-004364 · doc4.xml · derivative · entry 1 Tregoning Kathleen · CIK 0001830764 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,320 Underlying: Common Stock · 54,320 shares Expires 2033-02-06 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:16 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 30,943 | $1.29 Strike: $1.74 | $39,916.47 |
DisclosureSEC source: 0000899243-23-000990 · doc4.xml · derivative · entry 1 Tregoning Kathleen · CIK 0001830764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,943 Underlying: Common Stock · 30,943 shares Expires 2033-01-03 F2 · price: This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $40,000 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy. F1 · derivative.exercise_date: This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 21:39 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-031497 · doc4.xml · nonDerivative · entry 1 Tregoning Kathleen · CIK 0001830764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on September 15, 2023, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 18:39 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 63,321 | $0.00 Strike: $30.36 | $0.00 |
DisclosureSEC source: 0000899243-22-005926 · doc4.xml · derivative · entry 1 Tregoning Kathleen · CIK 0001830764 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,321 Underlying: Common Stock · 63,321 shares Expires 2032-02-09 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 9, 2023, with the remainder vesting in thirty-six (36) monthly installments thereafter. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 22:13 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 4,428 | $9.03 Strike: $13.19 | $39,984.84 |
DisclosureSEC source: 0000899243-22-001380 · doc4.xml · derivative · entry 1 Tregoning Kathleen · CIK 0001830764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,428 Underlying: Common Stock · 4,428 shares Expires 2032-01-05 F2 · price: This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $40,000 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy. F1 · derivative.exercise_date: This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:14 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $16.91 | $0.00 |
DisclosureSEC source: 0000899243-21-044352 · doc4.xml · derivative · entry 1 Tregoning Kathleen · CIK 0001830764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-11-11 F1 · derivative.exercise_date: The shares underlying this option will vest in thirty-six equal monthly installments at the end of each successive month following November 11, 2021, subject to the Reporting Person's continued service as a director through the applicable vesting dates. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 18:50 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 77,399 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0000899243-21-005101 · doc4.xml · derivative · entry 1 Tregoning Kathleen · CIK 0001830764 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,399 Underlying: Common Stock · 77,399 shares Expires 2031-02-03 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 3, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 19:05 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 78,229 | $0.00 Strike: $15.45 | $0.00 |
DisclosureSEC source: 0000899243-20-033034 · doc4.xml · derivative · entry 1 Tregoning Kathleen · CIK 0001830764 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,229 Underlying: Common Stock · 78,229 shares Expires 2030-12-04 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on December 4, 2021, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.